WHO Drug Information Vol. 25, No. 2, 2011

Proposed INN: List 105 WHO Drug Information Vol. 25, No. 2, 2011tabalumabtabalumabimmunoglobuline G4-kappa, anti-[Homo sapiens TNFSF13B(membre 13B de la superfamille du facteur de nécrose tumorale,BAFF, THANK, TALL-1, TALL1, BLYS, BLyS, facteur d'activationdes cellules B, stimulateur des lymphocytes B, CD257)], Homosapiens anticorps monoclonal;chaîne lourde gamma4 (1-450) [Homo sapiens VH (IGHV4-34*01(100.00%) -(IGHD)-IGHJ4*01) [8.7.17] (1-123) -IGHG4*01 charnièreS10>P (231) (124-450)], (137-214')-disulfure avec la chaîne légèrekappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*05 (108'-214')]; dimère (229-229'':232-232'')-bisdisulfureimmunomodulateurinmunoglobulina G4-kappa, anti-[TNFSF13B de Homo sapiens(miembro 13B de la superfamilia del factor de necrosis tumoral,BAFF, THANK, TALL-1, TALL1, BLYS, BLyS, factor de activación decélulas B, estimulante de linfocitos B, CD257)], Homo sapiensanticuerpo monoclonal;cadena pesada gamma4 (1-450) [VH de Homo sapiens (IGHV4-34*01 (100.00%) -(IGHD)-IGHJ4*01) [8.7.17] (1-123) -IGHG4*01bisagra S10>P (231) (124-450)], (137-214')-disulfuro con la cadenaligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01(97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*05 (108'-214')]; dímero(229-229'':232-232'')-bisdisulfuroinmunomodulador1143503-67-6Heavy chain / Chaîne lourde / Cadena pesadaQVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQP PGKGLEWIGE 50INHSGSTNYN PSLKSRVTIS VDTSKNQFSL KLSSVTAADT AVYYCARGYY 100DILTGYYYYF DYWGQGTLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP 250KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN 300STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ 350VYTLPPSQEE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400LDSDGSFFLY SRLTVDKSRW QEGNVFSCSV MHEALHNHYT QKSLSLSLGK 450Light chain / Chaîne légère / Cadena ligeraEIVLTQSPAT LSLSPGERAT LSCRASQSVS RYLAWYQQKP GQAPRLLIYD 50ASNRATGIPA RFSGSGSGTD STLTISSLEP EDFAVYYCQQ RSNWPRTFGQ 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSNTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-95 150-206 264-324 370-42822''-95'' 150''-206'' 264''-324'' 370''-428''Intra-L 23'-88' 134'-194'23'''-88''' 134'''-194'''Inter-H-L 137-214' 137''-214'''Inter-H-H 229-229'' 232-232''N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación300, 300''tefinostatumtefinostatcyclopentyl (2S)-2-[({4-[8-(hydroxyamino)-8-oxooctanamido]phenyl}methyl)amino]-2-phenylacetateantineoplastic196